Kidney Research and Clinical Practice10.23876/j.krcp.21.0152021403383-391Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylureaNam-Jun Cho, Dae-Yeon Kim, Soon Hyo Kwon, Tae Won Ha, Hyun Kyu Kim, Man Ryul Lee, Sung Wan Chun, Samel Park, Eun-young Lee, Hyo-Wook Gil,,
Patient Preference and Adherence10.2147/ppa.s1096642016Volume 101539-1546Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metforminXiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee Varnado, Jay Bae
Diabetes, Obesity and Metabolism10.1111/j.1463-1326.2006.00704.x200792194-205Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialM. A. Nauck, G. Meininger, D. Sheng, L. Terranella, P. P. Stein,,
Diabetes, Obesity and Metabolism10.1111/dom.120922013159810-818Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitusT. Kadowaki, K. Kondo,
Diabetes10.2337/db18-195-lb201867Supplement 1195-LBLower Risk of Dementia in Elderly Patients Initiated on Dipeptidyl Peptidase-4 Inhibitor vs. Sulfonylurea—A Population-Based Cohort StudySEUNG JIN HAN, JA YOUNG JEON, KWANWOO LEE, TAE HO KIM, HYUN UK MOON
Japanese Clinical Medicine10.4137/jcm.s857120123JCM.S8571Combination Therapy with a Dipeptidyl peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes MellitusKoichi Hirao, Hajime Maeda, Shin-ichiro Shirabe, Ritsuko Yamamoto, Tetsuyuki Hirao, Setsuko Hirao, Mikio Yamauchi, Keiko Arai,,
Diabetes & Metabolism10.1016/j.diabet.2017.03.010201844195-96Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?C. Amouyal, P. Levy, F. Andreelli, A. Hartemann,
Diabetic Medicine10.1111/j.1464-5491.2010.03181.x2011284464-469Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetesJ. Rosenstock, A. J. Lewin, P. Norwood, V. Somayaji, T. T. Nguyen, J. G. Teeter, S. L. Johnson, H. Dai, S. G. Terra,
Endocrinology and Metabolism10.3803/enm.2021.2032021362339-341New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 InhibitorsChan-Hee Jung,,
Cancer Management and Research10.2147/cmar.s2151072019Volume 117427-7438

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

Yeo Jin Choi, Dae Jung Kim, Sooyoung Shin,